Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade? by Blower, P & Aapro, M
Granisetron vs ondansetron: is it a question of duration of 5-HT3
receptor blockade?
P Blower*
,1 and M Aapro
2
1Poole House, Great Yeldham, Halstead, Essex CO9 4HP, UK;
2Clinique de Genolier, 1272, Genolier, Switzerland
DOI: 10.1038/sj/bjc/6600313 www.bjcancer.com
ã 2002 Cancer Research UK
Sir
We read with interest the publication by de Wit et al (2001) that
there may be effective cross-over to granisetron after failure on
ondansetron; both are selective 5-HT3 receptor antagonists, a class
of drugs considered the ‘gold-standard’ antiemetic agents for the
control of emesis in cancer patients undergoing chemo- and radio-
therapy. While we support the outcome that granisetron
demonstrates superior efﬁcacy to ondansetron, an effect that has
been previously reported by Terrey and Aapro (1996), we have
some concerns about the study design and the authors’ interpreta-
tion of the results.
Firstly, from the outset this study favours granisetron. We recog-
nise that the trial of de Wit et al (2001) involved only a small
number of patients (n=40), however, for the study to be a balanced
cross-over design, patients should have been selected from a back-
ground of failure on both ondansetron and granisetron with
previous chemotherapy cycles. Moreover, the authors fail to discuss
the possibility of a psychological bias toward the introduction of
the ‘new’ drug. Psychological factors can inﬂuence treatment
success and are known to be associated with anticipatory nausea
and vomiting, a negative phenomenon that can have potentially
disabling effects on patients undergoing successive chemotherapy
cycles. Conversely, there may be positive psychological elements
beneﬁting the patient – the design of this trial does not control
for this effect. In double-blind trials in which patients fail on
one antiemetic treatment and then go on to receive the antiemetic
in subsequent cycles, anticipation of a switch in therapy may be
enough to demonstrate an improved response.
Despite its importance to the interpretation of the study results,
de Wit et al (2001) have made no reference to the longer duration
of action of granisetron vs ondansetron, nor the pharmacodynamic
properties of the two agents. Compelling data accumulated from
cutaneous ﬂare experiments in human volunteers demonstrate that,
following a single infusion of granisetron, 40 mgk g
71, the 5-HT3
receptor-mediated axon ﬂare reﬂex is signiﬁcantly reduced for at
least 24 h (Cooper et al, 1988; Upward et al, 1990). This contrasts
with a 2.6-fold shorter duration of action after infusion with
ondansetron, 8 and 16 mg (Sweetland et al, 1992) and is further
supported by the longer plasma half-life of granisetron (about
10 h; Carmichael et al, 1989) compared with ondansetron (about
3.8 h; Roila and Del Favero, 1995). Furthermore, granisetron
differs from the competitive antagonist ondansetron in that it
displays insurmountable antagonism at vagal afferent 5-HT3 recep-
tors (Newberry et al, 1993), and it is this property that is thought
to underlie the phenomenon that its pharmacodynamic half-life far
exceeds its plasma half-life.
The authors fail to acknowledge further important data in their
discussion. The two chemotherapeutic agents administered in
this study, cisplatin (4=50 mg m
72) and cyclophosphamide
(4=500 mg m
72), differ in their emetogenic potential as well as
the time of onset of their emetic action (Doherty, 1999) (Table
1). While de Wit et al (2001) report complete protection following
cisplatin-based chemotherapy in two out of seven patients receiving
granisetron and none out of six patients receiving ondansetron, the
principal difference between the efﬁcacy of ondansetron and gran-
isetron in this study was following cyclophosphamide-based
therapy. Fifty-eight per cent of patients receiving cyclophospha-
mide experienced complete protection of emesis following a
single dose of granisetron, compared with 7% following a single
dose of ondansetron; the later onset of emesis following cyclopho-
sphamide must favour the longer duration of antiemetic effect of
granisetron.
Additionally, de Wit et al (2001) state that, ‘there are no data
to support the use of higher doses of the same 5-HT3 receptor
antagonists in patients failing the recommended dosage,’ citing
Gandara et al (1998). However, a dose-related response
(P50.001) for oral dolasetron has been shown between doses of
25 and 200 mg (complete response rates 60.5 and 76.3% for
100 and 200 mg dolasetron, respectively; Fauser et al, 1996),
despite a recommended dosage for the agent of 100 mg. Similar
dose-related effects have also been reported with ondansetron.
For example, a Phase I study comparing three doses of intrave-
nous ondansetron t.d.s. (0.015, 0.15 and 0.3 mg kg
71) indicated
a trend towards increased efﬁcacy with higher doses (complete
response rates were 15, 46 and 58% respectively), though only
Table 1 Emetogenic potential and onset of emetic response following





Cisplatin 4=50 mg m
72 High 490% 1.5–3 h
Cyclophosphamide 4=500 mg m
72 Moderate 30–60% 9–12 h *Correspondence: P Blower;
E-mail: peter@rblower.freeserve.co.uk
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71 dose was shown to be signiﬁcantly different
from the other dose levels (Grunberg, 1992). Further studies have
reported signiﬁcantly superior efﬁcacy with a single dose on
ondansetron, 32 mg, compared with a single 8 mg dose (Beck et
al, 1992; Tsavaris et al, 2001). Moreover, studies comparing gran-
isetron, 40 and 160 mgk g
71, show a trend towards increased
efﬁcacy at the higher dose (Smith, 1993; Soukop, 1994); 24 h after
administration of chemotherapeutic agents, 81% of granisetron,
160 mcg kg
71, were emesis-free compared with 75% receiving
granisetron 40 mgk g
71 (Smith, 1993). In addition, patients refrac-
tory to other 5-HT3 receptor antagonists have been shown to
respond well to granisetron, at doses that are higher than gener-
ally used, in subsequent chemotherapy cycles (Carmichael et al,
1998).
In conclusion, the effective ‘switch’ to granisetron in this study
may, therefore, be due to a number of factors, but is likely to be
attributable primarily to the longer duration of action of granise-
tron compared with ondansetron rather than the lack of cross
resistance between 5-HT3 receptor antagonists.
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